08/06/2025
“Our findings suggest that the 8 mg dose of aflibercept may provide additional anatomic benefits over the 2 mg dose in patients with DME who need more frequent dosing. Additionally, the 8 mg dose may decrease treatment burden in those who do not require more frequent dosing.” – Ashkan Abbey, MD, Texas Retina Associates
On behalf of the PHOTON study investigators, Dr. Abbey delivered an on-demand presentation for the American Society of Retina Specialists (ASRS) 43rd Annual Scientific Meeting held last weekend. The PHOTON study was a multicenter, randomized, double-masked study where patients with diabetic macular edema (DME) were randomized 1:2:1 to one of three treatment groups.
Learn more in our latest blog: https://www.texasretina.com/2025/08/06/dr-abbey-delivered-on-demand-presentation-about-the-photon-dme-study-for-asrs-2025-meeting